Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

In8Bio Inc (INAB)

In8Bio Inc (INAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,466
  • Shares Outstanding, K 4,218
  • Annual Sales, $ 0 K
  • Annual Income, $ -30,440 K
  • EBIT $ -21 M
  • EBITDA $ -18 M
  • 60-Month Beta 0.02
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.63

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.20
  • Number of Estimates 1
  • High Estimate -1.20
  • Low Estimate -1.20
  • Prior Year -1.20
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5301 +15.68%
on 11/07/25
2.1080 -16.03%
on 12/01/25
+0.1400 (+8.59%)
since 11/05/25
3-Month
1.5301 +15.68%
on 11/07/25
2.6500 -33.21%
on 10/08/25
-0.3950 (-18.24%)
since 09/05/25
52-Week
1.5301 +15.68%
on 11/07/25
12.5310 -85.88%
on 02/11/25
-7.2300 (-80.33%)
since 12/05/24

Most Recent Stories

More News
IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Presented new preclinical data on INB-619, a novel gamma-delta (γδ) T cell engager (TCE), demonstrating equivalent potency comparable to FDA-approved commercial products with minimal adverse cytokine...

INAB : 1.7700 (-2.75%)
IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site

NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases,...

INAB : 1.7700 (-2.75%)
IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications

INB-619 demonstrated equivalent efficacy to the FDA approved, commercial T Cell Engagers (TCE) compounds, blinatumomab and mosunetuzumab, with minimal adverse cytokine release, highlighting a targeted...

INAB : 1.7700 (-2.75%)
IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications

INB-619 demonstrated equivalent efficacy to the FDA approved, commercial T Cell Engagers (TCE) compounds, blinatumomab and mosunetuzumab, with minimal adverse cytokine release, highlighting a targeted...

INAB : 1.7700 (-2.75%)
Mizuho Securities Reaffirms Their Buy Rating on IN8bio (INAB)

Mizuho Securities analyst Uy Ear maintained a Buy rating on IN8bio today and set a price target of $4.00. The company’s shares closed today at $2.10.Elevate Your Investing Strategy: Take advantage of...

INAB : 1.7700 (-2.75%)
IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Delivered an oral presentation at ASCO 2025 Annual Meeting, demonstrating extended median progression-free survival (mPFS) in patients receiving multiple doses of INB-200, including a patient remaining...

INAB : 1.7700 (-2.75%)
Next-Gen Cancer Treatments Gain Steam Amid Oncology Industry Shakeups

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Cancer rates are climbing across the U.S., with stark disparities from state to state. Recent CDC data...

ONCY : 0.9921 (+1.16%)
INAB : 1.7700 (-2.75%)
ONC.TO : 1.42 (+2.16%)
TNGX : 9.63 (-2.73%)
MBIO : 1.2500 (-5.30%)
ELVN : 21.81 (+1.92%)
IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial

INAB : 1.7700 (-2.75%)
IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival

INAB : 1.7700 (-2.75%)
IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025

INAB : 1.7700 (-2.75%)

Business Summary

IN8bio Inc. is a clinical-stage biotechnology company. It focuses on developing therapies for the treatment of cancers, including solid tumors using allogeneic, autologous, and genetically modified gamma-delta T cells. The company's principal candidate includes INB-200, which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 1.9832
2nd Resistance Point 1.9365
1st Resistance Point 1.8533
Last Price 1.7700
1st Support Level 1.7234
2nd Support Level 1.6767
3rd Support Level 1.5935

See More

52-Week High 12.5310
Fibonacci 61.8% 8.3287
Fibonacci 50% 7.0306
Fibonacci 38.2% 5.7324
Last Price 1.7700
52-Week Low 1.5301

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar